Tag Archives: Argot Partners

Zynerba

Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock

DEVON, Pa., Jan. 19, 2017 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the pricing of an underwritten public offering of 2.8 million shares of its common stock at a price of $18.00 per share, with expected gross proceeds to Zynerba of $50.4 million.

Zynerba

Zynerba Pharmaceuticals to Participate in Upcoming Investor Meetings and Conferences

DEVON, Pa., June 1, 2016 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will participate in various upcoming investor meetings and conferences.

Zynerba

Zynerba Pharmaceuticals to Present at 28th Annual ROTH Conference

DEVON, Pa., March 7, 2016 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will present at the 28th Annual ROTH Conference.


Top